June 4, 2020 / 1:26 PM / a month ago

BRIEF-Elixirgen Therapeutics Concludes Pre-IND Meeting With FDA For Covid-19 Vaccine Candidate EXG-5003

June 4 (Reuters) -

* ELIXIRGEN THERAPEUTICS CONCLUDES PRE-IND MEETING WITH FDA FOR ITS COVID-19 VACCINE CANDIDATE EXG-5003

* ELIXIRGEN THERAPEUTICS - CONTINUING ACTIVE DEVELOPMENT OF EXG-5003 TOWARD A PLANNED PHASE I CLINICAL TRIAL Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below